We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.82B
AUM Growth
+$1.31B
Cap. Flow
+$158M
Cap. Flow %
2.03%
Top 10 Hldgs %
19.27%
Holding
869
New
65
Increased
350
Reduced
240
Closed
81

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$43.7M
2
BMY icon
Bristol-Myers Squibb
BMY
+$30.4M
3
GILD icon
Gilead Sciences
GILD
+$28.3M
4
BIIB icon
Biogen
BIIB
+$26.7M
5
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$25.2M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$75.2M
2
LOXO
Loxo Oncology, Inc
LOXO
+$28.1M
3
DHR icon
Danaher
DHR
+$27.9M
4
A icon
Agilent Technologies
A
+$26.4M
5
MKC icon
McCormick & Company Non-Voting
MKC
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 33.36%
2 Technology 15.96%
3 Financials 11.25%
4 Consumer Discretionary 8.98%
5 Communication Services 7.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TFCF
826
DELISTED
Twenty-First Century Fox, Inc. Class B
TFCF
– –
-24,895
Closed -$1.19M
NTRI
827
DELISTED
NutriSystem, Inc.
NTRI
– –
-50,466
Closed -$2.21M
ELGX
828
DELISTED
Endologix Inc
ELGX
– –
-14,000
Closed -$100K
NXEO
829
DELISTED
Nexeo Solutions, Inc. Common Stock
NXEO
– –
-116,732
Closed -$1M
NXTM
830
DELISTED
NxStage Medical Inc.
NXTM
– –
-92,842
Closed -$2.66M
LOXO
831
DELISTED
Loxo Oncology, Inc
LOXO
– –
-200,673
Closed -$28.1M
AHL
832
DELISTED
ASPEN Insurance Holding Limited
AHL
– –
-106,600
Closed -$4.48M
NFX
833
DELISTED
Newfield Exploration
NFX
– –
-77,219
Closed -$1.13M
ATHN
834
DELISTED
Athenahealth, Inc.
ATHN
– –
-51,115
Closed -$6.74M
DNB
835
DELISTED
Dun & Bradstreet
DNB
– –
-31,800
Closed -$4.54M
SEND
836
DELISTED
SendGrid, Inc.
SEND
– –
-159,219
Closed -$6.87M
VVC
837
DELISTED
Vectren Corporation
VVC
– –
-31,500
Closed -$2.27M
WRD
838
DELISTED
WildHorse Resource Development
WRD
– –
-49,998
Closed -$705K
ESIO
839
DELISTED
Electro Scientific Industries
ESIO
– –
-51,378
Closed -$1.54M
DM
840
DELISTED
Dominion Energy Midstream Ptr LP
DM
– –
-115,548
Closed -$2.08M
TSRO
841
DELISTED
TESARO, Inc.
TSRO
– –
-80,000
Closed -$5.94M
IMPV
842
DELISTED
Imperva, Inc.
IMPV
– –
-41,500
Closed -$2.31M
EGL
843
DELISTED
Engility Holdings, Inc.
EGL
– –
-69,669
Closed -$1.98M
NSU
844
DELISTED
Nevsun Resources Ltd.
NSU
– –
-537,300
Closed -$2.36M
SHPG
845
DELISTED
Shire pic
SHPG
– –
-47,698
Closed -$8.3M
30 31 32 33
34

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q1 2019 Portfolio in Review

As of Q1 2019, Candriam SCA held 869 positions worth $7.82B, up 20% from $6.51B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Candriam SCA's Q1 2019 filing shows 65 new, 350 increased, 240 reduced and 81 closed positions. Its largest new stake was Baozun: 640,000 shares worth $26.6M. The largest sale was Celgene Corp, an estimated $75.2M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 35% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q1 2019 buy was Baozun: 640,000 shares worth $26.6M.
  • Candriam SCA added most to Merck in Q1 2019, an estimated $43.7M increase.
  • Candriam SCA's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $75.2M.
  • Candriam SCA fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $28.1M.
  • Candriam SCA's ten largest holdings make up 19% of its $7.82B portfolio in Q1 2019.
  • Candriam SCA opened 65 new positions and closed 81 in Q1 2019.
  • Candriam SCA's portfolio value rose 20% quarter-over-quarter to $7.82B.

Based on Candriam SCA's 13F filing for Q1 2019, filed 2 May 2019.